Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death

Epigenetic alterations, including methylation, have been shown to be an important mechanism of gene silencing in cancer. Ependymoma has been well characterized at the DNA copy number and mRNA expression levels. However little is known about DNA methylation changes. To gain a more global view of the methylation profile of ependymoma we conducted an array-based analysis. Our data demonstrated tumors to segregate according to their location in the CNS, which was associated with a difference in the global level of methylation. Supratentorial and spinal tumors displayed significantly more hypermethylated genes than posterior fossa tumors, similar to the ‘CpG island methylator phenotype’ (CIMP) identified in glioma and colon carcinoma. This hypermethylated profile was associated with an increase in expression of genes encoding for proteins involved in methylating DNA, suggesting an underlying mechanism. An integrated analysis of methylation and mRNA expression array data allowed us to identify methylation-induced expression changes. Most notably genes involved in the control of cell growth and death and the immune system were identified, including members of the JNK pathway and PPARG. In conclusion, we have generated a global view of the methylation profile of ependymoma. The data suggests epigenetic silencing of tumor suppressor genes is an important mechanism in the pathogenesis of supratentorial and spinal, but not posterior fossa ependymomas. Hypermethylation correlated with a decrease in expression of a number of tumor suppressor genes and pathways that could be playing an important role in tumor pathogenesis.

[1]  A. Cimini,et al.  PPARγ‐dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF) , 2005, International journal of cancer.

[2]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Kitazawa,et al.  Epigenetic Alteration by DNA Promoter Hypermethylation of Genes Related to Transforming Growth Factor-β (TGF-β) Signaling in Cancer , 2011, Cancers.

[4]  D. Ahlquist,et al.  Frequent Methylation of Eyes Absent 4 Gene in Barrett's Esophagus and Esophageal Adenocarcinoma , 2005, Cancer Epidemiology Biomarkers & Prevention.

[5]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[6]  A. Feinberg,et al.  Reduced genomic 5-methylcytosine content in human colonic neoplasia. , 1988, Cancer research.

[7]  Jonathan Pevsner,et al.  DNA methylation signatures within the human brain. , 2007, American journal of human genetics.

[8]  Luigi Ferrucci,et al.  Abundant Quantitative Trait Loci Exist for DNA Methylation and Gene Expression in Human Brain , 2010, PLoS genetics.

[9]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[10]  J. Grill,et al.  Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. , 2006, Cancer genetics and cytogenetics.

[11]  T. Bestor,et al.  The DNA methyltransferases of mammals. , 2000, Human molecular genetics.

[12]  H. Colman,et al.  Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression , 2010, Clinical Cancer Research.

[13]  M. T. McCabe,et al.  Cancer DNA Methylation: Molecular Mechanisms and Clinical Implications , 2009, Clinical Cancer Research.

[14]  Flavio Giordano,et al.  Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Bird,et al.  Methylation-Induced Repression— Belts, Braces, and Chromatin , 1999, Cell.

[16]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[17]  Ingo Ruczinski,et al.  Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart , 2005, Genome Biology.

[18]  T. Kim,et al.  Chemotherapeutic DNA-damaging drugs activate interferon regulatory factor-7 by the mitogen-activated protein kinase kinase-4-cJun NH2-terminal kinase pathway. , 2000, Cancer research.

[19]  F. Latif,et al.  Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. , 2005, Cancer research.

[20]  J. Issa Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  J. Lowe,et al.  Pediatric Ependymoma: Biological Perspectives , 2009, Molecular Cancer Research.

[22]  E. Chiocca,et al.  Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. , 2010, Neuro-oncology.

[23]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[24]  K. Wright,et al.  New chemotherapy strategies and biological agents in the treatment of childhood ependymoma , 2009, Child's Nervous System.

[25]  Akira Teramoto,et al.  The c-Jun NH2-terminal kinase3 (JNK3) gene: genomic structure, chromosomal assignment, and loss of expression in brain tumors , 2001, Journal of Human Genetics.

[26]  F. Berthold,et al.  Analysis of HIC‐1 methylation and transcription in human ependymomas , 2004, International journal of cancer.

[27]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[28]  Kristin L. Sainani,et al.  Both location and age predict survival in ependymoma: A SEER study , 2009, Pediatric blood & cancer.

[29]  N. Normanno,et al.  A novel case of rhabdoid colon carcinoma associated with a positive CpG island methylator phenotype and BRAF mutation. , 2011, Human pathology.

[30]  H. Chu,et al.  DNA-methylation profiling distinguishes malignant melanomas from benign nevi , 2011, Pigment cell & melanoma research.

[31]  Nicholas K. Foreman,et al.  Immune Gene and Cell Enrichment Is Associated with a Good Prognosis in Ependymoma1 , 2009, The Journal of Immunology.

[32]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[33]  Hidetoshi Shimodaira,et al.  Pvclust: an R package for assessing the uncertainty in hierarchical clustering , 2006, Bioinform..

[34]  M. Soares,et al.  Epigenomic analysis of Alu repeats in human ependymomas , 2010, Proceedings of the National Academy of Sciences.

[35]  C. Caldas,et al.  Cancer genetics of epigenetic genes. , 2007, Human molecular genetics.

[36]  P. Rakic,et al.  The Jnk1 and Jnk2 Protein Kinases Are Required for Regional Specific Apoptosis during Early Brain Development , 1999, Neuron.

[37]  A. Cimini,et al.  Biomolecular characterization of human glioblastoma cells in primary cultures: Differentiating and antiangiogenic effects of natural and synthetic PPARγ agonists , 2008, Journal of cellular physiology.

[38]  Douglas C. Miller,et al.  Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue , 2007, Pediatric blood & cancer.

[39]  Peter W. Laird,et al.  DNA Methylation Profiles of Ovarian Epithelial Carcinoma Tumors and Cell Lines , 2010, PloS one.

[40]  A. Jeltsch,et al.  Biochemistry and biology of mammalian DNA methyltransferases , 2004, Cellular and Molecular Life Sciences CMLS.

[41]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[42]  H. Nagase,et al.  Genome-wide survey reveals dynamic widespread tissue-specific changes in DNA methylation during development , 2011, BMC Genomics.

[43]  J. Rey,et al.  Aberrant CpG Island Methylation of Multiple Genes in Ependymal Tumors , 2004, Journal of Neuro-Oncology.

[44]  Q Wang,et al.  Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer , 2007, Oncogene.

[45]  Mark J. Dunning,et al.  BASH: a tool for managing BeadArray spatial artefacts , 2008, Bioinform..

[46]  Amar Gajjar,et al.  Cross-species genomics matches driver mutations and cell compartments to model ependymoma , 2010, Nature.

[47]  G. Borsani,et al.  EYA4, a novel vertebrate gene related to Drosophila eyes absent. , 1999, Human molecular genetics.

[48]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[49]  R. Godbout,et al.  Fatty acid binding proteins in brain development and disease. , 2010, The International journal of developmental biology.

[50]  Q. Tao,et al.  Epigenetic disruption of two proapoptotic genes MAPK10/JNK3 and PTPN13/FAP-1 in multiple lymphomas and carcinomas through hypermethylation of a common bidirectional promoter , 2006, Leukemia.

[51]  T. Wolfsberg,et al.  DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status , 2008, Leukemia.

[52]  P. Rakic,et al.  Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene , 1997, Nature.

[53]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[54]  Michael D. Taylor,et al.  The genetic and epigenetic basis of ependymoma , 2009, Child's Nervous System.

[55]  P. Rakic,et al.  A critical role of neural-specific JNK3 for ischemic apoptosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[56]  C. Miller,et al.  Developmental expression in the mouse nervous system of the p493F12 SAP kinase. , 1996, Brain research. Molecular brain research.

[57]  D. Ellison,et al.  Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. , 2005, Cancer letters.

[58]  F. Scaravilli,et al.  CDKN2A, CDKN2B and p14 ARF are frequently and differentially methylated in ependymal tumours , 2003, Neuropathology and applied neurobiology.

[59]  F. Scaravilli,et al.  Expression profiling of ependymomas unravels localization and tumor grade‐specific tumorigenesis , 2009, Cancer.

[60]  C Eng,et al.  Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. , 2001, Human molecular genetics.

[61]  David Yang,et al.  Identification of cervical cancer markers by cDNA and tissue microarrays. , 2003, Cancer research.

[62]  Joe C. Adams,et al.  Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia , 1999, Nature Genetics.

[63]  B. Christensen,et al.  DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. , 2011, Journal of the National Cancer Institute.

[64]  Walter Kolch,et al.  RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. , 2007, Molecular cell.

[65]  Amar Gajjar,et al.  Radial glia cells are candidate stem cells of ependymoma. , 2005, Cancer cell.

[66]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[67]  D. Feinstein,et al.  Inhibition of in Vivo Glioma Growth and Invasion by Peroxisome Proliferator-Activated Receptor γ Agonist Treatment , 2006, Molecular Pharmacology.

[68]  R. Yuen,et al.  Extensive epigenetic reprogramming in human somatic tissues between fetus and adult , 2011, Epigenetics & Chromatin.

[69]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[70]  Jean-Yves Delattre,et al.  Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. , 2011, Neuro-oncology.

[71]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[72]  G. Pfeifer,et al.  The RASSF proteins in cancer; from epigenetic silencing to functional characterization. , 2009, Biochimica et biophysica acta.

[73]  Xueyan Zhong,et al.  High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer , 2008, Proceedings of the National Academy of Sciences.

[74]  E. Snyder,et al.  A Novel, Immortal, and Multipotent Human Neural Stem Cell Line Generating Functional Neurons and Oligodendrocytes , 2007, Stem cells.

[75]  Y. Owada,et al.  Spatio-temporally differential expression of genes for three members of fatty acid binding proteins in developing and mature rat brains , 1996, Journal of Chemical Neuroanatomy.

[76]  K. D. Sørensen,et al.  Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas , 2011, International journal of cancer.